KP-100IT not checked

Kringle Pharma, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“The contents of each vial were dissolved in the distilled water for injection, and the study drug (0.6 mg as KP-100) was administered intrathecally once per week a total of 5 times.”In the company’s words, NCT07722962 on ClinicalTrials.gov
Tested for
Acute Spinal Cord Injury (SCI)
Main trialPhase 3
“This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.”In the company’s words, NCT07722962 on ClinicalTrials.gov
Other names
Hepatocyte Growth Factor · HGF

Other drugs for Acute Spinal Cord Injury (SCI)

All 3 drugs for Acute Spinal Cord Injury (SCI)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 31 Dec 2028 Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
Phase 3Unknown 31 Dec 2022 Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow KP-100IT

Following is part of Solo: you see every change to KP-100IT the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in